🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Fawzi Abu Rous, MD Eric K. Singhi, MD Aakash Desai, MD, MPH, FASCO Jill Feldman EGFR Resisters Happy launch-day-eve!!

Mark your calendars for TOMORROW!!!! Eric K. Singhi, MD Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Jill Feldman Oncology News Central

What is the role of Dato-Dxd in EGFR+ NSCLC? JTO & JTO CRR - pooled analysis TropionLung01+05 - 117pts (med. 3 lines) - ORR 43%, mPFS 5.8m, mOS 15.6m - 60% stomatitis, g3+ 9% Reasonable option, though data not in the era of MARIPOSA+/-2 OncoAlert #LCSM jto.org/article/S1556-…

A pooled analysis of datopotamab deruxtecan in patients with EGFR–mutated NSCLC - Journal of Thoracic Oncology jto.org/article/S1556-… JTO & JTO CRR LungCancerRx 🫁💊 Interesting analysis ahead of U.S. FDA PDUFA date: July 12, 2025 Will we see another option in EGFRm NSCLC? OncoAlert

🎙️ Our podcast LungCancerRx 🫁💊 is live! We kicked things off with Jill Feldman, who shared her powerful #lungcancer story and path to #advocacy. Proud to launch this project with Eric K. Singhi, MD & Aakash Desai, MD, MPH, FASCO in collaboration with Oncology News Central. #LCSM #Oncology #PodcastLaunch

Great interview on LungCancerRx 🫁💊 with Jill Feldman on her #lungcancer experience and path to becoming a leader in #patientadvocacy. EGFR Resisters #LCSM

The LungCancerRx 🫁💊 podcast is live! 🎧 We talked about empowerment, the importance of communication, and the lived experience - not just the diagnosis, but the impact, decisions, scanxiety, etc. I've told my story many times in many settings. This was different because my family

🚨 Just published! Frontiers - Oncology Our review on HER2-altered #NSCLC — from biology 🧬 & testing to latest therapies 🔗 bit.ly/HER2NSCLC 🔑 #biomarker testing: tissue and #ctDNA 💥 ADCs & TKIs: T-DXd, zongertinib, A166, ARX788 📈 Future: combo trials & next-gen agents With

New U.S. FDA accelerated approval: Dato-DXd for EGFR+ NSCLC after prior EGFR therapy + platinum chemo. ▫️n=114, TROPIONLung01&05 ▫️ORR: 45% ▫️DoR: 6.5 mo ⚠️ ILD, ocular AEs, stomatitis, embryo-fetal risk OncoAlert #lcsm

🚨 FDA Accelerated Approval (June 23, 2025) Datopotamab deruxtecan (Datroway) approved for adults with EGFR-mutated NSCLC post EGFR-TKI + platinum chemotherapy ➡️ORR: 45% ⏳ DOR: 6.5 mo 📌 Pooled from TROPION-Lung01 & Lung05 ⚠️ ILD/pneumonitis, stomatitis, ocular AEs included

One page takeaway from #LUMINOSITY study that resulted in Teliso-V FDA Oncology approval for c-met overexpression metastatic NSCLC. #OncTwitter #MedTwitter #lcsm D. Ross Camidge OncoAlert

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who

🚀 Introducing Lung Cancer Hackers — a powerhouse team of brilliant 🇯🇴 medical students skilled in big data and driven by a passion for cancer research. I’m proud to mentor this group — they already have 6 abstracts accepted to #WCLC25! #LCSM #Oncology #MedTwitter

Ending Lung Cancer Task Force is here! Proud to be part of this terrific team!

Huge thanks to Dr. Fawzi Abu Rous, MD for his limitless mentorship and guidance. It really means a lot! Very proud to be part of this all-star team🌟

So excited to be working with such an intelligent and passionate team. Huge shoutout to Dr.Fawzi Abu Rous, MD for being an incredible mentor and teaming us up!

Sunvozertinib (oral EGFR inhibitor, 200mg Qd) now U.S. FDA approved based off PhII WU-KONG1 in previously treated Exon20ins mNSCLC: - Confirmed 44.9% ORR w/ 9mos DoR: 57% - ≥Gr 3: Diarrhea (17%), CPK levels (11%), and anemia (3.6%) #OncTwitter #MedTwitter

New U.S. FDA accelerated approval: Sunvozertinib for EGFR exon20ins NSCLC after platinum chemo ▫️n=85, WU-KONG1B ▫️ORR: 46% ▫️DoR: 11.1 mo ⚠️ Diarrhea, rash, ⬆️ CK OncoAlert Exon 20 Group, a multistakeholder organization #lcsm

Have you caught up on Episode 1 of LungCancerRx 🫁💊 yet? Your refill is almost due… because Episode 2 drops NEXT WEEK! 🎧💥 Oncology News Central Eric K. Singhi, MD Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Jill Feldman